Pages that link to "Q35771332"

The following pages link to Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen (Q35771332):

Displaying 45 items.

• IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques (Q24630281) (← links)
• Immunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent Model (Q27345320) (← links)
• Perspectives for therapeutic HPV vaccine development (Q28069272) (← links)
• Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model (Q28652354) (← links)
• DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. (Q33598307) (← links)
• The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice (Q33645729) (← links)
• DNA vaccines for cervical cancer (Q33680693) (← links)
• Co-Administration of a Plasmid DNA Encoding IL-15 Improves Long-Term Protection of a Genetic Vaccine against Trypanosoma cruzi (Q33847435) (← links)
• Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions (Q33862762) (← links)
• Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. (Q33897405) (← links)
• Therapeutic HPV DNA vaccines (Q33936427) (← links)
• Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity (Q34033407) (← links)
• Immunotherapy for cervical cancer: Research status and clinical potential (Q34033763) (← links)
• SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. (Q34065110) (← links)
• Immune therapy for human papillomaviruses-related cancers (Q34657561) (← links)
• Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses (Q35049821) (← links)
• Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge (Q35087579) (← links)
• Clinical applications of DNA vaccines: current progress (Q35452312) (← links)
• Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen. (Q36184362) (← links)
• DNA vaccines, electroporation and their applications in cancer treatment (Q36256459) (← links)
• A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 cervical intraepithelial neoplasia 2/3 (CIN2/3). (Q36494733) (← links)
• Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity (Q36757129) (← links)
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri (Q36954152) (← links)
• Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG. (Q36978363) (← links)
• DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies (Q37010987) (← links)
• DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection (Q37626311) (← links)
• Oncogenic impact of human papilloma virus in head and neck cancer (Q37762309) (← links)
• Codon usage roles in human papillomavirus (Q37949297) (← links)
• Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. (Q38133178) (← links)
• Current state in the development of candidate therapeutic HPV vaccines (Q38743922) (← links)
• The current state of therapeutic and T cell-based vaccines against human papillomaviruses (Q39033576) (← links)
• Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. (Q41068034) (← links)
• Transforming activity of a novel mutant of HPV16 E6E7 fusion gene (Q42809528) (← links)
• In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8 T cells (Q45324266) (← links)
• E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response (Q45370701) (← links)
• DNA Vaccines: A Strategy for Developing Novel Multivalent TB Vaccines (Q50861643) (← links)
• Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. (Q52691583) (← links)
• Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. (Q54255264) (← links)
• Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. (Q55163909) (← links)
• Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes (Q64244575) (← links)
• Therapeutic HPV DNA vaccines (Q84504653) (← links)
• Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis (Q89511647) (← links)
• A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer (Q90165928) (← links)
• Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses (Q90248447) (← links)
• Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation (Q92650506) (← links)